Nuvalent growth playbook

Add a short, consented HCP sign-up (name, specialty, practice ZIP, NPI optional, topics: clinical data, practice and access resources, congress highlights) on the home, data and practice resources pages. Send a PRC-approved welcome series: the practice resources (EHR order sets, ordering guide), Nuvalent Patient Support and the About ROS1+ NSCLC testing page. Feed sign-ups to the CRM so field teams see engagement.

Rare-biomarker brands reach few prescribers, so every HCP who self-identifies is worth keeping in touch with. An owned list is also the channel for whatever comes next, at no media cost.

[ ] Fields: name, specialty, ZIP, NPI optional, topics
[ ] Consent and opt-out wording approved
[ ] Form on home, data and practice resources pages
[ ] Welcome email 1: practice resources and EHR order sets
[ ] Welcome email 2: Nuvalent Patient Support
[ ] Welcome email 3: ROS1 testing page
[ ] CRM sync for field teams
[ ] Monthly KPI report

• Compliance delays

  Start with already-approved content in the emails.

• Low volume

  Promote the sign-up in rep emails and at congresses.

• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source
• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source
• Your websiteHCP practice resources: EHR instructions for Epic, Oracle Health (Cerner), iKnowMed and OncoEMR, an Ordering Guide and ICD-10 codes. Ordering: "in-office dispensing or Biologics by McKesson, the exclusive specialty pharmacy"; Patient Assistance, Quick Start, Bridge and Copay Assistance programs through Nuvalent Patient Support; template letters of medical necessity, exception and appeal.Source
• Your websiteHCP site About ROS1+ NSCLC: ROS1 fusions are "found in 1%-2% of people with the disease"; patients "may: Be young, never smokers", "Develop brain metastases"; fusions are detected with DNA-based (FISH, NGS) and RNA-based (PCR, NGS) tests that "can be more accurate when used together", and DNA-based NGS "can miss certain ROS1 fusions".Source

Point the approval banner to /our-medicines, add clear "For US healthcare professionals" and "For US patients" buttons on the homepage, add /our-medicines to the sitemap with a canonical tag, and take the job-link URLs out of the sitemap.

It turns corporate-site traffic, which spikes with every GSK announcement, into visits to the approved HCP and patient information.

• Corporate site rules under GSK

  Agree the change with GSK communications.

• Your websitenuvalent.com homepage (checked October 21, 2026): "As of July 15, 2026, GSK has completed the acquisition of Nuvalent. READ MORE" and "New Approved Therapy for Locally Advanced ROS1+ NSCLC! READ MORE" both link to gsk.com press releases. The homepage has no link to the JIDEYTRO patient or HCP sites; the menu item "Our Medicines" is the only route. The page has no canonical tag and no structured data.Source
• Your websitenuvalent.com sitemap: 15 URLs, including three /jobs?gh_jid= job links, /expanded-access-policy and /our-responsibility, but not /our-medicines. /our-medicines links to the patient site, the HCP site, the Prescribing Information, NuvalentPatientSupport.com and MedInfo, and describes Nuvalent Patient Support as helping "navigate coverage and costs".Source
• News coverageGSK completed its acquisition of Nuvalent, adding three lung cancer assets: zidesamtinib, neladalkib (under FDA review for ALK-positive NSCLC) and NVL-330 for HER2-altered NSCLC. In May 2026 Nuvalent said "TKI-naïve expansion strategies are underway", its "U.S. commercial and medical affairs teams are in place" for "multiple synergistic launches in biomarker-driven NSCLC", and it appointed a Chief International Officer to lead expansion outside the US.Source

Rename the frame "Request a JIDEYTRO representative", send a conversion event when a request is submitted, report requests by page and source, and route them to the right territory within one business day.

Rep requests are the clearest sign of HCP intent; they should be measured and answered fast.

• None meaningful

  Test after the change.

• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source
• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source

Make the EHR resources a field and email priority: a one-page "add JIDEYTRO to your EHR" guide for practice pharmacists and informatics staff, delivered by reps and in the HCP welcome series, with downloads tracked by practice.

Removing friction at ordering helps prescribing, and practice staff are an audience that brand campaigns rarely reach.

• Practices cannot share install data

  Track downloads and ask in rep calls.

• Your websiteHCP practice resources: EHR instructions for Epic, Oracle Health (Cerner), iKnowMed and OncoEMR, an Ordering Guide and ICD-10 codes. Ordering: "in-office dispensing or Biologics by McKesson, the exclusive specialty pharmacy"; Patient Assistance, Quick Start, Bridge and Copay Assistance programs through Nuvalent Patient Support; template letters of medical necessity, exception and appeal.Source
• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source

Change the Sitemap line on both sites to the live /sitemap_index.xml, make sure non-public build hosts are not referenced or reachable publicly, and submit both sitemaps in Search Console.

Correct sitemaps get updated pages, such as new resources or safety updates, indexed quickly.

• None meaningful

  Check robots.txt after each release.

• Your websiterobots.txt on both jideytro.com and jideytrohcp.com declares a sitemap on a different, non-public development host rather than the live domain, although the live domains serve working sitemaps (/sitemap_index.xml with page-sitemap.xml).Source
• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source
• Your websitePatient site jideytro.com (14 pages): what ROS1+ NSCLC is, how JIDEYTRO was studied, results, safety and side effects, taking JIDEYTRO, FAQs, patient support, resources, "advocacy-support-groups" and "stay-connected".Source

Build one monthly dashboard: HCP site visits by section, resource downloads, sign-ups, rep requests, email engagement, speaker program attendance and field feedback, by territory. Agree targets per tactic.

Shared numbers let the team move budget to what reaches prescribers.

• Agency data delays

  Make monthly data delivery part of contracts.

• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source
• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source
• HiringDirector, National Thought Leader Liaison (remote): engagement "for lung cancer thought leaders, including academic researchers, digital opinion leaders, and other key influencers" as the company prepares launches; identifies promotional speakers and the "brand Speaker Bureau"; supports "KOL videos, Peer to Peer programs, Product theaters"; must be "Proficient in multichannel marketing directed towards HCPs and patients, including digital, media, peer-to-peer, congresses".Source

With Medical Affairs leading, create non-promotional education on ROS1 testing (when to add RNA-based testing, how to read reports) for pathologists, molecular labs and oncology nurses, delivered through medical education partners, congress symposia and an unbranded page.

Better testing grows the identified ROS1 population, which helps patients and every downstream effort.

• Seen as promotional

  Keep it unbranded and Medical-owned.

• Your websiteHCP site About ROS1+ NSCLC: ROS1 fusions are "found in 1%-2% of people with the disease"; patients "may: Be young, never smokers", "Develop brain metastases"; fusions are detected with DNA-based (FISH, NGS) and RNA-based (PCR, NGS) tests that "can be more accurate when used together", and DNA-based NGS "can miss certain ROS1 fusions".Source
• HiringDirector, Medical Affairs Strategy (remote): advisory boards, symposia, congress planning and educational initiatives; "a key Medical Affairs contributor on the Promotional Review Committee (PRC) and Medical Review Committee (MRC)"; the Investigator-Sponsored Research (ISR) program; and gathering "scientific and clinical insights from KOL interactions, advisory boards, and scientific conferences".Source
• News coverageGSK: the FDA approved Jideytro (zidesamtinib) "for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor", ahead of the 18 September 2026 target date, after Breakthrough Therapy and Orphan Drug designations; it is "GSK's first approval in lung cancer". About 50,000 people worldwide are diagnosed with ROS1-positive NSCLC each year, often non-smokers in their 40s and 50s.Source

Record approved speaker programs and product theaters (where allowed), host them on the HCP site with registration, offer live virtual sessions at evening times, and send highlights to opted-in HCPs.

Each program reaches many more prescribers for the same speaker and review cost.

• Compliance limits

  Use PRC-approved formats only.

• HiringDirector, National Thought Leader Liaison (remote): engagement "for lung cancer thought leaders, including academic researchers, digital opinion leaders, and other key influencers" as the company prepares launches; identifies promotional speakers and the "brand Speaker Bureau"; supports "KOL videos, Peer to Peer programs, Product theaters"; must be "Proficient in multichannel marketing directed towards HCPs and patients, including digital, media, peer-to-peer, congresses".Source
• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source
• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source

Identify lung cancer clinicians with active professional audiences, engage them under contract for approved content (case-based discussions, testing education via Medical), and track reach. Disclose all paid relationships.

Peer voices carry more weight than brand messages with specialists.

• Disclosure lapses

  Central approval and monitoring.

• HiringDirector, National Thought Leader Liaison (remote): engagement "for lung cancer thought leaders, including academic researchers, digital opinion leaders, and other key influencers" as the company prepares launches; identifies promotional speakers and the "brand Speaker Bureau"; supports "KOL videos, Peer to Peer programs, Product theaters"; must be "Proficient in multichannel marketing directed towards HCPs and patients, including digital, media, peer-to-peer, congresses".Source
• HiringDirector, Medical Affairs Strategy (remote): advisory boards, symposia, congress planning and educational initiatives; "a key Medical Affairs contributor on the Promotional Review Committee (PRC) and Medical Review Committee (MRC)"; the Investigator-Sponsored Research (ISR) program; and gathering "scientific and clinical insights from KOL interactions, advisory boards, and scientific conferences".Source

Make a one-page access guide for nurses, financial counsellors and office managers: which program when, how to enroll, the specialty pharmacy path, and the template letters. Train field reimbursement staff to walk practices through it.

Faster starts and fewer drop-offs are among the biggest levers for a specialty oncology brand.

• Data from the hub is partial

  Track hub-reported starts first.

• Your websiteHCP practice resources: EHR instructions for Epic, Oracle Health (Cerner), iKnowMed and OncoEMR, an Ordering Guide and ICD-10 codes. Ordering: "in-office dispensing or Biologics by McKesson, the exclusive specialty pharmacy"; Patient Assistance, Quick Start, Bridge and Copay Assistance programs through Nuvalent Patient Support; template letters of medical necessity, exception and appeal.Source
• Your websitenuvalent.com sitemap: 15 URLs, including three /jobs?gh_jid= job links, /expanded-access-policy and /our-responsibility, but not /our-medicines. /our-medicines links to the patient site, the HCP site, the Prescribing Information, NuvalentPatientSupport.com and MedInfo, and describes Nuvalent Patient Support as helping "navigate coverage and costs".Source

Work with patient advocacy groups (within compliance rules) on what newly diagnosed patients need: understanding biomarker testing, questions to ask the care team, living with brain metastases. Support their own programs with grants where appropriate.

Trusted community voices reach patients earlier and help them ask about testing and options.

• Independence concerns

  Keep grants arm's length and disclosed.

• Your websitePatient site jideytro.com (14 pages): what ROS1+ NSCLC is, how JIDEYTRO was studied, results, safety and side effects, taking JIDEYTRO, FAQs, patient support, resources, "advocacy-support-groups" and "stay-connected".Source
• Your websitePatient site: the "Stay connected" page also links to advocacy and support groups ("Share your experiences and receive support") and FAQs; the HCP site links "For patients" to jideytro.com.Source
• Your websiteHCP site About ROS1+ NSCLC: ROS1 fusions are "found in 1%-2% of people with the disease"; patients "may: Be young, never smokers", "Develop brain metastases"; fusions are detected with DNA-based (FISH, NGS) and RNA-based (PCR, NGS) tests that "can be more accurate when used together", and DNA-based NGS "can miss certain ROS1 fusions".Source
• News coverageGSK: the FDA approved Jideytro (zidesamtinib) "for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor", ahead of the 18 September 2026 target date, after Breakthrough Therapy and Orphan Drug designations; it is "GSK's first approval in lung cancer". About 50,000 people worldwide are diagnosed with ROS1-positive NSCLC each year, often non-smokers in their 40s and 50s.Source

Give reps approved email templates (data summary, dosing, access guide, EHR order sets) to send from the CRM after a visit, and track which ones HCPs open. Feed results to the Advisory Board.

Timely follow-up reinforces the visit and shows marketing which content field conversations need.

• Off-label risk in free text

  Templates only, no free text.

• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source
• Your websiteHCP practice resources: EHR instructions for Epic, Oracle Health (Cerner), iKnowMed and OncoEMR, an Ordering Guide and ICD-10 codes. Ordering: "in-office dispensing or Biologics by McKesson, the exclusive specialty pharmacy"; Patient Assistance, Quick Start, Bridge and Copay Assistance programs through Nuvalent Patient Support; template letters of medical necessity, exception and appeal.Source

Add a "Request medical information" form to the HCP site, routed to Medical Information with response time targets, and log questions by theme to inform medical strategy.

Fast, documented answers support appropriate use and feed real questions back to Medical.

• Adverse events in requests

  Route to pharmacovigilance automatically.

• Your websitenuvalent.com sitemap: 15 URLs, including three /jobs?gh_jid= job links, /expanded-access-policy and /our-responsibility, but not /our-medicines. /our-medicines links to the patient site, the HCP site, the Prescribing Information, NuvalentPatientSupport.com and MedInfo, and describes Nuvalent Patient Support as helping "navigate coverage and costs".Source
• HiringDirector, Medical Affairs Strategy (remote): advisory boards, symposia, congress planning and educational initiatives; "a key Medical Affairs contributor on the Promotional Review Committee (PRC) and Medical Review Committee (MRC)"; the Investigator-Sponsored Research (ISR) program; and gathering "scientific and clinical insights from KOL interactions, advisory boards, and scientific conferences".Source
• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source

Add a one-question feedback prompt on HCP site pages ("Did this page answer your question?"), combine with advisory board and field themes monthly, and turn top gaps into approved resources.

Content built from real questions gets used, and the loop gives the tactical plan evidence.

• Off-label questions

  Route clinical questions to Medical Information.

• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source
• HiringDirector, Medical Affairs Strategy (remote): advisory boards, symposia, congress planning and educational initiatives; "a key Medical Affairs contributor on the Promotional Review Committee (PRC) and Medical Review Committee (MRC)"; the Investigator-Sponsored Research (ISR) program; and gathering "scientific and clinical insights from KOL interactions, advisory boards, and scientific conferences".Source
• HiringDirector, National Thought Leader Liaison (remote): engagement "for lung cancer thought leaders, including academic researchers, digital opinion leaders, and other key influencers" as the company prepares launches; identifies promotional speakers and the "brand Speaker Bureau"; supports "KOL videos, Peer to Peer programs, Product theaters"; must be "Proficient in multichannel marketing directed towards HCPs and patients, including digital, media, peer-to-peer, congresses".Source

With Patient Support, offer enrolled patients scheduled nurse or educator check-ins and approved reminders about what to expect, how to report side effects and when to call the care team.

Supporting patients through the first months helps them and their care teams manage treatment.

• Medical advice risk

  Educators refer clinical questions to the care team.

• Your websitenuvalent.com sitemap: 15 URLs, including three /jobs?gh_jid= job links, /expanded-access-policy and /our-responsibility, but not /our-medicines. /our-medicines links to the patient site, the HCP site, the Prescribing Information, NuvalentPatientSupport.com and MedInfo, and describes Nuvalent Patient Support as helping "navigate coverage and costs".Source
• Your websitePatient site: the "Stay connected" page also links to advocacy and support groups ("Share your experiences and receive support") and FAQs; the HCP site links "For patients" to jideytro.com.Source
• Your websitePatient site jideytro.com (14 pages): what ROS1+ NSCLC is, how JIDEYTRO was studied, results, safety and side effects, taking JIDEYTRO, FAQs, patient support, resources, "advocacy-support-groups" and "stay-connected".Source

Design a shared HCP platform: one consent and preference record per HCP (by brand and topic), shared resources for testing and access, and brand-specific sections added only as each is approved. Align with GSK's HCP systems during integration.

The same oncologists treat ALK, ROS1 and HER2 patients; one relationship is easier for them and cheaper to run.

• Integration changes plans

  Build on systems GSK will keep.

• News coverageGSK completed its acquisition of Nuvalent, adding three lung cancer assets: zidesamtinib, neladalkib (under FDA review for ALK-positive NSCLC) and NVL-330 for HER2-altered NSCLC. In May 2026 Nuvalent said "TKI-naïve expansion strategies are underway", its "U.S. commercial and medical affairs teams are in place" for "multiple synergistic launches in biomarker-driven NSCLC", and it appointed a Chief International Officer to lead expansion outside the US.Source
• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source
• Your websitejideytrohcp.com (12 pages in its sitemap): efficacy, intracranial activity, ARROS-1 study design, safety, dosing, About ROS1+ NSCLC, patient support, practice resources and "Talk to a representative". The only HCP form is the rep request, an embedded form whose frame is titled "Nuvalent Patient Sign Up". There is no sign-up for HCP updates, while the patient site jideytro.com has a "Stay connected" page: "Sign up for more information and occasional updates on JIDEYTRO and ROS1+ NSCLC".Source

Turn the US HCP site, access materials and testing education into a modular kit (local language, local label, local access programs) that country teams can adapt once they have approval.

A tested kit cuts time and cost per country and keeps the science consistent.

• Different rules per market

  Local review before any use.

• News coverageGSK completed its acquisition of Nuvalent, adding three lung cancer assets: zidesamtinib, neladalkib (under FDA review for ALK-positive NSCLC) and NVL-330 for HER2-altered NSCLC. In May 2026 Nuvalent said "TKI-naïve expansion strategies are underway", its "U.S. commercial and medical affairs teams are in place" for "multiple synergistic launches in biomarker-driven NSCLC", and it appointed a Chief International Officer to lead expansion outside the US.Source
• News coverageGSK: the FDA approved Jideytro (zidesamtinib) "for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor", ahead of the 18 September 2026 target date, after Breakthrough Therapy and Orphan Drug designations; it is "GSK's first approval in lung cancer". About 50,000 people worldwide are diagnosed with ROS1-positive NSCLC each year, often non-smokers in their 40s and 50s.Source
• Your websiteHCP practice resources: EHR instructions for Epic, Oracle Health (Cerner), iKnowMed and OncoEMR, an Ordering Guide and ICD-10 codes. Ordering: "in-office dispensing or Biologics by McKesson, the exclusive specialty pharmacy"; Patient Assistance, Quick Start, Bridge and Copay Assistance programs through Nuvalent Patient Support; template letters of medical necessity, exception and appeal.Source

Publish clear ISR priorities based on the top HCP questions (for example sequencing and patients with brain metastases), review proposals against them, and share results at congresses and in publications.

Independent evidence on practical questions builds lasting trust with prescribers.

• Slow research cycles

  Prioritise feasible studies.

• HiringDirector, Medical Affairs Strategy (remote): advisory boards, symposia, congress planning and educational initiatives; "a key Medical Affairs contributor on the Promotional Review Committee (PRC) and Medical Review Committee (MRC)"; the Investigator-Sponsored Research (ISR) program; and gathering "scientific and clinical insights from KOL interactions, advisory boards, and scientific conferences".Source
• Your websiteHCP site About ROS1+ NSCLC: ROS1 fusions are "found in 1%-2% of people with the disease"; patients "may: Be young, never smokers", "Develop brain metastases"; fusions are detected with DNA-based (FISH, NGS) and RNA-based (PCR, NGS) tests that "can be more accurate when used together", and DNA-based NGS "can miss certain ROS1 fusions".Source
• HiringDirector, National Thought Leader Liaison (remote): engagement "for lung cancer thought leaders, including academic researchers, digital opinion leaders, and other key influencers" as the company prepares launches; identifies promotional speakers and the "brand Speaker Bureau"; supports "KOL videos, Peer to Peer programs, Product theaters"; must be "Proficient in multichannel marketing directed towards HCPs and patients, including digital, media, peer-to-peer, congresses".Source

Show a still image first and load the video after, inline critical CSS, raise text contrast and name icon links.

A faster, accessible corporate site helps patients and HCPs on older devices and supports GSK's accessibility standards.

• Design change

  Keep the video, only delay it.

• Google PageSpeednuvalent.com: real Chrome users see the main content in 1.5 s at the 75th percentile, Interaction to Next Paint 117 ms and layout shift 0.02, so visitors pass Core Web Vitals. The mobile lab score is 82 with LCP 3.5 s; the largest element is a protein rendering video and render-blocking requests cost about 1.6 s. Accessibility flags low-contrast text and links without discernible names.Source
• Your websitenuvalent.com homepage (checked October 21, 2026): "As of July 15, 2026, GSK has completed the acquisition of Nuvalent. READ MORE" and "New Approved Therapy for Locally Advanced ROS1+ NSCLC! READ MORE" both link to gsk.com press releases. The homepage has no link to the JIDEYTRO patient or HCP sites; the menu item "Our Medicines" is the only route. The page has no canonical tag and no structured data.Source

Add a short plain-language summary to each publication, group them by program, and link to congress presentations. Keep it non-promotional and reviewed.

Clear science communication supports recruitment, partnerships and trust during the GSK transition.

• Seen as promotion

  Non-promotional review and no product claims.

• Your websitenuvalent.com homepage (checked October 21, 2026): "As of July 15, 2026, GSK has completed the acquisition of Nuvalent. READ MORE" and "New Approved Therapy for Locally Advanced ROS1+ NSCLC! READ MORE" both link to gsk.com press releases. The homepage has no link to the JIDEYTRO patient or HCP sites; the menu item "Our Medicines" is the only route. The page has no canonical tag and no structured data.Source
• News coverageGSK completed its acquisition of Nuvalent, adding three lung cancer assets: zidesamtinib, neladalkib (under FDA review for ALK-positive NSCLC) and NVL-330 for HER2-altered NSCLC. In May 2026 Nuvalent said "TKI-naïve expansion strategies are underway", its "U.S. commercial and medical affairs teams are in place" for "multiple synergistic launches in biomarker-driven NSCLC", and it appointed a Chief International Officer to lead expansion outside the US.Source

Give each piece (visual aid, leave-behinds, emails) a simple quarterly score from the field (used, useful, HCP reaction) alongside usage data, and retire or improve the lowest scorers.

Materials that reps actually use are the ones HCPs see.

• Survey fatigue

  Keep it to three questions.

• HiringDirector, JIDEYTRO HCP Marketing (remote, posted October 15, 2026): supports "the company's first LCM indication launch for JIDEYTRO in ROS1+ NSCLC (TKI naïve)" while advancing "the current in-market indication for TKI-pretreated ROS1+ NSCLC"; works "with Digital Marketing on digital assets for HCPs (websites, emails, banners, etc.)"; leads the HCP tactical plan "with clear budget allocation and KPIs", "Peer-to-Peer and Congress strategy", the Core Visual Aid with Medical, Legal and Regulatory review, field sales training and the "JIDEYTRO Field Sales Advisory Board"; and must "Adapt ... as organization navigates GSK integration".Source